Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Medicines Company Is Almost Ready To Celebrate Angiomax Patent Term Extension

This article was originally published in The Pink Sheet Daily

Executive Summary

Studies of additional indications for the product may resume as the Patent and Trademark Office assesses the potential length of the extension, which could protect the product until mid-2015.
Advertisement

Related Content

Angiomax Generic From Hospira Might Launch At-Risk Launch In 2015
Patent Reform Clears House, But Provisions On PTO Fees, Patent Term Extension Differ From Senate
Patent Reform Clears House, But Provisions On PTO Fees, Patent Term Extension Differ From Senate
Legal News, In Brief: Copaxone, AngioMax, Cipro, Botox, OxyContin
Legal News, In Brief: Copaxone, AngioMax, Cipro, Botox, OxyContin
Angiomax Patent Term Extension: Will Second Time Be The Charm?

Topics

Advertisement
UsernamePublicRestriction

Register

PS071401

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel